Premium
Local application of recombinant human fibroblast growth factor‐2 on bone repair: A dose–escalation prospective trial on patients with osteotomy
Author(s) -
Kawaguchi Hiroshi,
Jingushi Seiya,
Izumi Toshihiro,
Fukunaga Masao,
Matsushita Takashi,
Nakamura Takashi,
Mizuno Kosaku,
Nakamura Toshitaka,
Nakamura Kozo
Publication year - 2007
Publication title -
journal of orthopaedic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.20315
Subject(s) - medicine , dose , osteotomy , osteoarthritis , adverse effect , high tibial osteotomy , surgery , clinical trial , pathology , alternative medicine
Based on preclinical evidence in animal models, the present study examined the clinical efficacy and safety of recombinant human fibroblast growth factor‐2 (rhFGF‐2) to accelerate bone repair in a dose‐escalation prospective trial. One of three dosages (200, 400 or 800 µg) of rhFGF‐2 in a biodegradable gelatin hydrogel was injected during surgery into the osteotomy site of 59 knee osteoarthritis patients undergoing high tibial osteotomy, and 57 of them were monitored for 16 weeks. The rhFGF‐2 dose dependently increased the percentage of patients with radiographic bone union, and decreased the average time needed for such union. The percentages of patients with an absence of pain and full‐weight bearing were also greater in the higher dosage groups than in the low dosage group, especially in the clinically critical periods 6, 8, and 10 weeks. Neither blood chemistries nor clinical adverse events were associated with the rhFGF‐2 dosages. We therefore conclude that the rhFGF‐2 in gelatin hydrogel dose dependently accelerated radiographic bone union of a surgical osteotomy with a safety profile at least at the dosages used, suggesting the clinical efficacy of this agent for bone repair. © 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 25:480–487, 2007